Patriot Financial Group Insurance Agency LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.7% during the first quarter, Holdings Channel reports. The fund owned 2,544 shares of the biopharmaceutical company’s stock after selling 184 shares during the period. Patriot Financial Group Insurance Agency LLC’s holdings in Gilead Sciences were worth $169,000 at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in GILD. Denver Investment Advisors LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $462,000. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Gilead Sciences by 8.9% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 173,086 shares of the biopharmaceutical company’s stock worth $12,514,000 after buying an additional 14,150 shares during the last quarter. Banco Santander S.A. acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $2,513,000. Foresters Investment Management Company Inc. boosted its position in shares of Gilead Sciences by 1.4% in the fourth quarter. Foresters Investment Management Company Inc. now owns 699,320 shares of the biopharmaceutical company’s stock worth $51,498,000 after buying an additional 9,600 shares during the last quarter. Finally, Focused Wealth Management Inc boosted its position in shares of Gilead Sciences by 24.1% in the fourth quarter. Focused Wealth Management Inc now owns 22,091 shares of the biopharmaceutical company’s stock worth $1,582,000 after buying an additional 4,296 shares during the last quarter. Institutional investors own 73.99% of the company’s stock.
Gilead Sciences, Inc. (NASDAQ GILD) opened at 75.94 on Monday. The stock’s 50 day moving average is $69.98 and its 200-day moving average is $68.63. The firm has a market capitalization of $99.18 billion, a PE ratio of 8.25 and a beta of 1.20. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $82.10.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. During the same quarter last year, the company posted $3.08 earnings per share. The company’s revenue for the quarter was down 8.2% compared to the same quarter last year. Equities analysts expect that Gilead Sciences, Inc. will post $8.72 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.52 per share. The ex-dividend date is Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.74%. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.
TRADEMARK VIOLATION WARNING: “Patriot Financial Group Insurance Agency LLC Reduces Stake in Gilead Sciences, Inc. (GILD)” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://stocknewstimes.com/2017/07/31/patriot-financial-group-insurance-agency-llc-reduces-stake-in-gilead-sciences-inc-gild.html.
A number of brokerages have issued reports on GILD. BMO Capital Markets restated an “outperform” rating and set a $82.00 target price (up previously from $72.00) on shares of Gilead Sciences in a research report on Thursday. Deutsche Bank AG restated a “buy” rating and set a $81.00 target price (up previously from $79.00) on shares of Gilead Sciences in a research report on Thursday. Jefferies Group LLC restated a “hold” rating and set a $83.00 target price on shares of Gilead Sciences in a research report on Thursday. Cowen and Company restated an “outperform” rating and set a $90.00 target price on shares of Gilead Sciences in a research report on Thursday. Finally, Zacks Investment Research upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $84.00 target price for the company in a research report on Friday. Twelve equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $80.31.
In other Gilead Sciences news, Director John Francis Cogan sold 9,943 shares of the stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total transaction of $668,666.75. Following the transaction, the director now owns 47,562 shares in the company, valued at $3,198,544.50. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $227,197,799. The disclosure for this sale can be found here. In the last quarter, insiders have sold 128,276 shares of company stock worth $9,190,610. Corporate insiders own 1.30% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
